每经AI快讯，有投资者在投资者互动平台提问：627海外进展缓慢，前景不明。F-652也是前景暗淡，请 问公司在今年或未来是否会对这两款药品的开发支出进行减值计提？ 亿帆医药（002019.SZ）11月25日在投资者互动平台表示，（1）公司自研项目亿立舒已于2023年度确认 无形资产并计提减值准备，本年度暂未发现减值迹象；（2）公司在研项目F-652本年度仍处研发进程 中，暂未发现减值迹象。 （文章来源：每日经济新闻） ...

（记者 胡玲） 亿帆医药（002019.SZ）11月25日在投资者互动平台表示，截至目前，F627在中、美、德三个国家正式 上市销售。 每经AI快讯，有投资者在投资者互动平台提问：请问截至目前，F627已经真正进入了多少个国家并正 式开始销售？ ...

格隆汇11月25日丨亿帆医药(002019.SZ)在投资者互动平台表示，合成生物项目处于竣工验收调试阶 段。 （原标题：亿帆医药(002019.SZ)：合成生物项目处于竣工验收调试阶段） ...

免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 董秘你在回复有关F652在临床试验推进沟通的问题已经长达四年了，在这个沟通过程中到底是公司管 理层不作为还是相关监管部门不作为呢？不会一直在进行无了期无效的沟通吧？ 投资者提问： 感谢您的关注与提问。2024年4月底亿一生物与监管机构召开了III类咨询沟通会，就在研项目F-652的 ACLF适应症后续临床试验设计的重点内容进行了讨论，公司结合监管机构的要求与建议进行反复论 证，评判风险，并适时动态调整。在国内优先推进确定性较强的aGVHD适应症的后续临床试验，目前 已提交临床试验申请。谢谢！查看更多董秘问答>> 董秘回答(亿帆医药SZ002019)： ...

董秘请问:近期公司的亿立舒收到泰国和马来西亚两国获得注册上市的批准，为什么不发公告呢？你这 样做有没有违反了上市公司有关信息披露的规定？ 董秘回答(亿帆医药SZ002019)： 登录新浪财经APP 搜索【信披】查看更多考评等级 投资者提问： 感谢您的关注与提问。公司根据《深圳证券交易所股票上市规则》、《公司章程》等规定履行信息披露 义务。对于未达到披露标准的，公司也尽量通过官网、投资者关系平台等便于投资者了解更多信息。谢 谢！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

亿帆医药（002019.SZ）11月25日在投资者互动平台表示，国内发货量同比上升。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问亿立舒今年三季度以来在国内的销量是否继续保 持着稳定的增长态势？ ...

Group 1 - The core point of the news is that HMO producer Baolingbao has completed the construction of 2,500 tons of production capacity, with major domestic companies as its clients [2] - Yifan Pharmaceutical has an initial designed capacity of 1,000 tons for HMO production, which has not yet commenced operations [2]

Core Viewpoint - The company, Yifan Pharmaceutical, has reported an increase in sales of its compound Lonicerae Flos and Forsythiae Fructus granules due to a rise in cold patients as winter approaches [1] Company Summary - Yifan Pharmaceutical confirmed that the sales of its compound Lonicerae Flos and Forsythiae Fructus granules have seen a notable increase recently [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company reported a revenue of 3.923 billion yuan for Q1-Q3 2025, a year-on-year increase of 1.67%, and a net profit of 388 million yuan, up 5.84% year-on-year [1]. - In Q3 2025, the company achieved a revenue of 1.288 billion yuan, a year-on-year increase of 5.01%, but a quarter-on-quarter decrease of 1.60% [1]. - The innovative drugs, Yili Shou and Yinikang, saw a combined sales revenue growth of 147.04% in Q1-Q3 2025, with Yili Shou's shipments increasing by 77.99% and Yinikang's by 315.76% [2]. - The clinical trial of the traditional Chinese medicine, Duanjin Jiedu Capsule, successfully demonstrated superior efficacy in preventing relapse compared to the placebo group [3]. Financial Performance - The company expects revenues of 6.101 billion, 7.137 billion, and 8.284 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 606 million, 819 million, and 1.061 billion yuan for the same years [6]. - The company reported a net profit of 84 million yuan in Q3 2025, a decrease of 25.64% year-on-year and 44.09% quarter-on-quarter [1]. - The self-owned pharmaceutical formulation products generated revenue of 2.969 billion yuan in Q1-Q3 2025, reflecting an 11.07% year-on-year increase [2]. Clinical Trials and Product Development - The A-319 (CD3&CD19 TCE bispecific antibody) showed good tolerance in clinical trials, with preliminary efficacy indicating a reduction in SLEDA I-2K scores [4][5]. - The Duanjin Jiedu Capsule demonstrated a significant increase in the negative rate of urine opioid substances, achieving a 95.2% negative rate compared to 68.6% in the placebo group [3]. Market Position and Valuation - The company has a total market capitalization of approximately 15.983 billion yuan, with a circulating market value of about 11.057 billion yuan [7]. - The company's earnings per share (EPS) is projected to be 0.50 yuan in 2025, with a price-to-earnings (P/E) ratio of 26.36 [10].

Group 1 - The company Yifan Pharmaceutical (002019) reported that as of October 31, 2025, the number of shareholders is expected to be 47,904 [1]